AbbVie's New ‘Biological Missile' Ovarian Cancer Treatment Gets Full FDA Approval

ToplineThe Food and Drug Administration said Friday it granted full approval to AbbVie and ImmunoGen’s cancer drug mirvetuximab-soravtansine-gynx, or Elahere, part of a new class of cancer treatments considered “biological missiles” because of their ability to precisely home in on cancer cells.FILE - A sign for the U.S. Food and Drug Administration is displayed outside their offices in Silver ... [+] Spring, Md., Dec. 10, 2020. (AP Photo/Manuel Balce Ceneta, File)Copyright 2020 The Associated Press. All rig ...